Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 4/20 | 0.52 |
| ▸ | HTT | P42858 | 3/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | TRPC5 | Q9UL62 | 2/20 | 0.50 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | DRD2 | P14416 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.47 |
| ▸ | KDM1A | O60341 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL7528105 | 0.99 | LMNA (0.51) | GRM2LMNAHTTSMN1; SMN2MAPT | |
| SCHEMBL7516307 | 0.84 | ALDH1A1 (0.57) | GRM2HTTSMN1; SMN2ALDH1A1DRD2 | |
| SCHEMBL7528484 | 0.84 | ALDH1A1 (0.58) | GRM2LMNASMN1; SMN2MAPTSLC2A1 | |
| Bromide SCHEMBL7520978 | 0.84 | ALDH1A1 (0.56) | GRM2HTTSMN1; SMN2ALDH1A1DRD2 | |
| SCHEMBL7527192 | 0.83 | HTR1A (0.62) | LMNASMN1; SMN2DRD2KDM4EHTR1A | |
| Bromide SCHEMBL7519489 | 0.83 | ALDH1A1 (0.57) | GRM2LMNASMN1; SMN2MAPTSLC2A1 | |
| Bromide SCHEMBL7526692 | 0.82 | HTR1A (0.61) | LMNASMN1; SMN2DRD2KDM4EHTR1A | |
| SCHEMBL8233241 | 0.77 | LMNA (0.82) | GRM2LMNAHTTSMN1; SMN2MAPT | |
| SCHEMBL7519980 | 0.74 | PHGDH (0.65) | GRM2SMN1; SMN2MAPTALDH1A1DRD2 | |
| Bromide SCHEMBL7525103 | 0.73 | PHGDH (0.64) | GRM2SMN1; SMN2MAPTALDH1A1DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020058666-A1 | 2-piperazinoalkylaminobenzoazole derivatives: dopamine receptor subtype specific ligands | NEUROGEN CORPORATION | 2002-05-16 | — | — | US | claimed |
| US-6284759-B1 | PSYCHOLOGICAL DISORDERS; NERVOUS SYSTEM DISORDERS | NEUROGEN CORPORATION | 2001-09-04 | — | — | US | claimed |
| US-6432958-B1 | FOR THERAPY AND PROPHYLAXIS OF NEUROPSYCHOLOGICAL DISORDERS SUCH AS SCHIZOPHRENIA, MANIA, DEMENTIA, DEPRESSION, ANXIETY, COMPULSIVE BEHAVIOR, SUBSTANCE ABUSE, MOTOR DISORDERS AND MOTION DISORDERS RELATED TO USE OF NEUROLEPTIC AGENT | NEUROGEN CORPORATION | 2002-08-13 | — | — | US | disclosed |
| US-20020058666-A1 | 2-piperazinoalkylaminobenzoazole derivatives: dopamine receptor subtype specific ligands | NEUROGEN CORPORATION | 2002-05-16 | — | — | US | disclosed |
| US-6284759-B1 | PSYCHOLOGICAL DISORDERS; NERVOUS SYSTEM DISORDERS | NEUROGEN CORPORATION | 2001-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020058666-A1 | 2-piperazinoalkylaminobenzoazole derivatives: dopamine receptor subtype specific ligands | CHRNA7, HTR7, OPRD1 | GRM2 84/4885LMNA 4356/4885HTT 308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.